对USP25和USP28抑制剂双特异性的结构基础
Jonathan Vincent Patzke1, Florian Sauer1, Radhika Karal Nair1
1Rudolf Virchow Center for Integrative and Translational Bioimaging, Institute for Structural Biology, Julius-Maximilians-University Würzburg, Würzburg, Germany.
向二性激酶 (USP28/USP25) 提供了一种新的癌症治疗策略. 研究人员用抑制剂对USP28进行结构性特征化,揭示出一种共同的结合口袋和一种关键的谷氨酸残留物,这对药物开发至关重要.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 癌症疗法在直接向瘤基因方面面临挑战.
- 稳定瘤基因的deubiquitylases (DUBs) 是一个有前途的治疗点.
- USP28和USP25是关键的DUBs与癌症有关,与现有的非选择性抑制剂.
研究的目的:
- 通过小分子抑制剂对USP28抑制进行结构性和功能性表征.
- 了解USP28和USP25的抑制机制.
- 确定开发选择性抑制剂的关键残留物和结合口袋.
主要方法:
- 使用抑制剂的USP28的结构特征 (AZ1,Vismodegib,FT206).
- 功能性测试用于评估酶活性和抑制.
- 现场定向突变发生,以调查关键残留物的作用.
主要成果:
- 抑制剂在USP28中结合到一个共同的口袋,解释了与USP28和USP25相对的类似功效.
- 保存的谷氨酸残留物 (E366/E373) 对于口袋稳定性,抑制剂结合和酶活性至关重要.
- 突变这种谷氨酸残留物会影响抑制剂结合和酶活性.
结论:
- 鉴定的共同结合口袋和关键的谷氨酸残留物为USP28/USP25抑制提供了洞察力.
- 针对这个口袋或突变谷氨酸酸可以促进选择性USP28或USP25抑制剂的发展.
- 这项研究通过准特定的二维性激素来推进开发新型癌症治疗方法的策略.
更多相关视频
06:30Using Phage Display to Develop Ubiquitin Variant Modulators for E3 Ligases
Published on: August 27, 2021
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
相关概念视频
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Ligand Binding and Linkage
Single-Strand DNA Binding Proteins
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
